全文获取类型
收费全文 | 6496篇 |
免费 | 287篇 |
国内免费 | 54篇 |
专业分类
耳鼻咽喉 | 197篇 |
儿科学 | 361篇 |
妇产科学 | 268篇 |
基础医学 | 443篇 |
口腔科学 | 309篇 |
临床医学 | 647篇 |
内科学 | 1555篇 |
皮肤病学 | 107篇 |
神经病学 | 357篇 |
特种医学 | 243篇 |
外科学 | 1331篇 |
综合类 | 113篇 |
预防医学 | 152篇 |
眼科学 | 266篇 |
药学 | 268篇 |
中国医学 | 5篇 |
肿瘤学 | 215篇 |
出版年
2024年 | 2篇 |
2023年 | 69篇 |
2022年 | 52篇 |
2021年 | 128篇 |
2020年 | 113篇 |
2019年 | 166篇 |
2018年 | 176篇 |
2017年 | 156篇 |
2016年 | 187篇 |
2015年 | 239篇 |
2014年 | 258篇 |
2013年 | 354篇 |
2012年 | 469篇 |
2011年 | 430篇 |
2010年 | 260篇 |
2009年 | 227篇 |
2008年 | 518篇 |
2007年 | 553篇 |
2006年 | 534篇 |
2005年 | 502篇 |
2004年 | 378篇 |
2003年 | 315篇 |
2002年 | 240篇 |
2001年 | 128篇 |
2000年 | 109篇 |
1999年 | 107篇 |
1998年 | 29篇 |
1997年 | 24篇 |
1996年 | 18篇 |
1995年 | 11篇 |
1994年 | 9篇 |
1993年 | 10篇 |
1992年 | 11篇 |
1991年 | 17篇 |
1990年 | 8篇 |
1989年 | 2篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1984年 | 2篇 |
1982年 | 2篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1975年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 3篇 |
1970年 | 3篇 |
1969年 | 2篇 |
1966年 | 1篇 |
排序方式: 共有6837条查询结果,搜索用时 31 毫秒
1.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
2.
3.
Yilmaz Hülya Fırtına Sinem Sarıtaş Merve Sayitoğlu Müge Ar Muhlis Cem 《Immunologic research》2022,70(6):811-816
Immunologic Research - Hyper immunoglobulin M (HIGM) syndrome is a rare disorder of the immune system with impaired antibody functions. The clinical picture of the patients varies according to the... 相似文献
4.
Kiran Naqvi MD Elias Jabbour MD Jeffrey Skinner BS MHA Kristin Anderson BS Sara Dellasala BS Musa Yilmaz MD Alessandra Ferrajoli MD Prithviraj Bose MD Philip Thompson MBBS Yesid Alvarado MD Nitin Jain MBBS Koichi Takahashi MD Jan Burger MD Zeev Estrov MD Gautam Borthakur MBBS Naveen Pemmaraju MD Shilpa Paul Pharm D Jorge Cortes MD Hagop M. Kantarjian MD 《Cancer》2020,126(1):67-75
5.
Zedef Dag Burcak Yilmaz Ayse Kutluhan Dogan Donay Unluer Aksan Huseyin Ozkurt Hazim Orhan Kızılkaya Deniz Arslan 《Brachytherapy》2019,18(2):154-162
Purpose
To evaluate the effect of metabolic parameters of pretreatment primary tumor and regional lymph nodes with F-18-FDG PET/CT compared with MRI findings for the prognostic value and disease-free survival (DFS) in locally advanced cervical cancer.Material and Methods
From 2011 to 2016, 112 patients with a diagnosis of cervical cancer stages IB2-IVA treated with concomitant chemoradiation therapy with 3D intracavitary brachytherapy were analyzed. From this group, 50 patients who underwent pretreatment and posttreatment FDG PET/CT and MRI were enrolled. LRFFS, DFS, and overall survival were analyzed in comparison with FDG PET/CT and MRI data. Relationship between SUVmax data and DFS was also assessed.Results
The median followup was 21 months, and median age was 54 years. The estimated 5-year locoregional failure-free survival, DFS, and overall survival rates were 87.4%, 70%, and 81%, respectively. DFS was 59.5% in patients with nodal metastases in FDG PET/CT and 100% in node negative patients (p:0,017). DFS was 50% and 79.4% in MRI node-positive and in node-negative patients, respectively (p:0,260). In addition, the nodal SUVmax (p: 0.005) and posttreatment response in FDG PET-CT (p < 0.001) were significant prognostic factors for DFS. Furthermore, primary tumor volume in MRI (p:0,982), node positivity in MRI (p:0,301), and response in posttreatment MRI (p:0,26) are not significant prognostic factors for DFS.Conclusion
As a result, FDG PET/CT has higher accuracy than MRI in detecting lymph node metastasis, and tumor volume reduction on FDG PET/CT images was greater than that on MRI images after CCRT. 相似文献6.
7.
8.
Psychiatric Quarterly - The aim of this study was to assess the bullying status of Syrian adolescent refugees in Turkey and identify factors that contribute to bullying. The adolescents aged... 相似文献
9.
10.